Immune Therapeutics, Inc. Files New Drug Application for Lodonol™ in Kenya to Target HIV Epidemic

ORLANDO, Fla., April 26, 2018 (GLOBE NEWSWIRE) via OTC PR WIRE Immune Therapeutics, Inc. (OTCQB:IMUN) ( Immune “IMUN” or the Company ), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, is pleased to announce that the Kenya Pharmacy and Poison Board filed IMUN’s New Drug Application (NDA) for Lodonal™, its lead drug candidate, thereby accepting the NDA for a full review. Kenya is experiencing an HIV The post Immune Therapeutics, Inc. Files New Drug Application for Lodonol™ in Kenya to Target HIV Epidemic appeared first on Public Wire.
http://bit.ly/2I16t9n